First-line Treatment of Apatinib in Elderly Patient of Advanced Gastric Carcinoma: A Case Report of NGS-driven Targeted Therapy

Yan Yang,Wuqiong Zhang,Jinghao Yao,Jing Liu,Shukui Qin,Qiong Wu
DOI: https://doi.org/10.1080/15384047.2018.1423917
2018-01-01
Cancer Biology & Therapy
Abstract:Gastric carcinoma (GC) is a common gastrointestinal malignancy with high incidence and mortality worldwide, and most patients are diagnosed in the late stages of disease. Palliative chemotherapy provides a survival benefit for patients with inoperable advanced GC. However, elderly patients who are unable to tolerate chemotherapy had worse prognosis due to lack of effective treatment. Herein we reported a Chinese elderly GC patient using next generation sequencing (NGS)-based tumor DNA analysis. Valuable gene variants of vascular endothelial growth factor (VEGF) A gene amplification were detected. Additionally, a novel NOTCH1-BPHL fusion has been identified. He received antiangiogenic drug apatinib and showed both good clinical and radiographic response, but eventually died of non-cancer related cause, with progression free survival time (PFS) and overall survival time (OS) up to 9.53months. This was the first GC case with apatinib usage as first-line treatment under the guidance of NGS gene profiling.
What problem does this paper attempt to address?